177 results about "Antibody molecule" patented technology

The invention discloses an anti-CLDN6 nano antibody and related application thereof, and relates to the field of antibodies. The invention provides an anti-CLDN6 nano antibody, which comprises HCDR1, HCDR2 and HCDR3 in a heavy chain variable region of which the amino acid sequence is as shown in SEQ ID NO: 4, the nano antibody has excellent antigen binding activity, high specificity and good affinity, has relatively strong killing activity on cells with high expression of CLDN6, and can be used for preparing anti-CLDN6 drugs. The requirements of CLDN6 positive tumor immunotherapy on efficient, specific and high-penetrability antibody molecules are met, and a new strategy and means are provided for tumor therapy.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

The present invention relates to the combined use of FcyRIIb (CD32B)- and CD20-specific antibodies, in particular to a method of treating a patient having target cells expressing FcyRIIb, the method comprising the combined administration of: (i) an antibody molecule specifically binding to a surface antigen of said target cells, said antibody molecule having an Fc domain capable of binding to FcyRIIb; and (ii) an agent inhibiting or reducing the binding between the Fc domain of said antibody molecule and FcyRIIb, characterized in that the patient is selected on the basis of an elevated level of FcyRIIb expression by his target cells.

The invention discloses a nano antibody targeting GPRC5D as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The nano antibody is generated by mixed immunization of a GPRC5D polypeptide antigen with a sequence shown as SEQ ID NO: 1 and a GPRC5D protein antigen with a sequence shown as SEQ ID NO: 2. The preparation method comprises the following steps: mixing the GPRC5D polypeptide antigen and the GPRC5D protein antigen to immunize alpaca, sampling blood, constructing an antibody library, screening a phage display antibody library, expressing protein, and selecting the nano antibody with the highest affinity. The invention further provides a radionuclide labeled molecular probe, the nano antibody is small in molecular weight and can recognize a large number of epitopes, and the molecular probe prepared from the nano antibody can obtain high-quality images, is used for preparing products for developing multiple myeloma or detecting GPRC5D expression level and has wide application prospects.

The present invention provides a method for identifying multifactorial interactions in a biological sample, comprising (a) selecting a plurality of analytical target factors, (b) labeling antibody molecules against each of the selected factors with DNA barcodes, (c) contacting a biological sample containing the analytical target factors with the antibody molecules labeled with the DNA barcodes, (d) embedding the biological sample in a hydrogel after step (c), (e) performing, within the hydrogel, a nucleic acid amplification reaction using a plurality of primers designed such that, when two antibodies come in close proximity, the primers produce an amplification product containing both DNA barcode sequences from the antibodies, and (f) analyzing a nucleotide sequence of the produced amplification product to detect a presence of a factor that simultaneously interacts with two or more factors.

The invention belongs to the technical field of biology, and particularly relates to a swine monoclonal antibody of hog cholera virus Erns protein. The amino acid sequence of a heavy chain variable region of the swine monoclonal antibody is shown as SEQ ID NO: 1, the amino acid sequence of a heavy chain constant region of the swine monoclonal antibody is shown as SEQ ID NO: 2, the amino acid sequence of a light chain variable region of the swine monoclonal antibody is shown as SEQ ID NO: 3, and the amino acid sequence of the light chain constant region of the swine monoclonal antibody is shown as SEQ ID NO: 4. The full-length genes of the heavy chain and the light chain of the swine monoclonal antibody are obtained from a swine B cell specifically amplified by the same hog cholera virus Erns protein, the natural structure of an antibody molecule is reserved, affinity loss possibly caused by artificial recombination is avoided, and the swine monoclonal antibody has high affinity and specificity, and can be used for preparing the swine monoclonal antibody. And a precise molecular tool is provided for antigen structure analysis of the hog cholera virus Erns protein and establishment of a hog cholera diagnosis method. The monoclonal antibody is applied to a blocking ELISA detection method of the hog cholera virus Erns antibody, and the established Erns antibody blocking ELISA detection method is high in sensitivity and strong in specificity.

The disclosure provides compositions and methods for the preparation, manufacture and use of an adeno-associated virus (AAV) particle for the vectorized delivery of an antibody molecule that binds to HER2.

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to a method of administering a BCMA-targeting agent which is an anti-BCMA antibody molecule or a recombinant non-antibody protein that binds to BCMA, and a gamma secretase inhibitor.

The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, meth

The invention relates to a fluorescently-labeled Prussian blue nano-particle as well as a preparation method and application thereof, the fluorescently-labeled Prussian blue nano-particle is prepared, and a carboxyl functional group is reserved on the surface of the nano-particle and is used for being subsequently coupled with an antigen or antibody molecule through a covalent bond. The nano material can provide colorimetric and fluorescent dual-mode detection functions, is beneficial to enhancing the detection sensitivity of an immunochromatography technology, and meanwhile, retains the detection convenience. The material is simple in preparation method, low in cost and easy for large-scale production and application.

The invention relates to an antibody specifically binding to TROP2 or an antigen binding fragment thereof. The invention also encompasses VHH antibodies or heavy chain antibodies that specifically bind to PD-L1. The invention further relates to a bispecific antibody which is constructed on the basis of the TROP2 antibody and the PD-L1 antibody and is specifically combined with the TROP2 and the PD-L1. The invention also encompasses immunoconjugates constructed based on the antibody molecules, such as antibody-conjugated drugs such as ADC. The invention further relates to a preparation method and application of the antibody molecule and the TROP2xPD-L1 targeting bispecific antibody coupling medicine.

Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and / or diagnose cancerous or infectious disorders.

Antibody molecules that specifically bind to NKp30 are disclosed. The anti-NKp30 antibody molecules can be used to treat, prevent and / or diagnose cancerous, autoimmune or infectious conditions and disorders.

The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

The combined use of a first antibody molecule that specifically binds to Fc [gamma] RIIb through its Fab region and binds to Fc [gamma] receptor through its Fc region and a second antibody molecule that specifically binds to PD-1 and binds to at least one Fc [gamma] receptor through its Fc region in the treatment of cancer in a patient having tumor-infiltrating T lymphocytes having medium or high PD-1 expression is described, as well as pharmaceutical compositions and kits comprising these two antibody molecules, as well as methods of using these two antibodies to treat cancer. A diagnostic test for identifying patients who benefit from the treatment described herein is also described.

Disclosed herein are methods for detecting cells expressing antibody molecules on the cell surface that bind to a targeted antigen without competing with one or more binding partners of the target antigen. Also disclosed herein are methods for detecting and differentiating cells expressing antibody molecules on the cell surface to a target antigen that are non-competing with one or more binding partners, from cells expressing antibody molecules to a target antigen that block binding by a binding partner. The methods disclosed herein allow for enrichment and isolation of cells expressing antibody molecules on the cell surface to a target antigen that are non-competing with one or more binding partners, and cells expressing antibody molecules on the cell surface to a target antigen that block binding by a binding partner.

Disclosed are anti-CD3 single domain antibodies and uses thereof. Also provided is a molecule, e.g., a bi-specific or multi-specific molecule, or an immunoconjugate, containing the single domain antibody. Additionally provided are nucleic acids encoding the antibody molecules, as well as vectors and host cells comprising the nucleic acids.

The invention relates to a nano antibody targeting claudin 18.2 and application thereof, and relates to the technical field of immunology and molecular biology. An amino acid sequence of a complementary determining region of the nano antibody for targeting claudin 18.2 comprises a CDR1 (Complementary Determining Region) as shown in SEQ ID NO: 1, a CDR2 (Complementary Determining Region) as shown in SEQ ID NO: 5 and a CDR3 (Complementary Determining Region) as shown in SEQ ID NO: 12. According to the invention, an alpaca immune bacteriophage display library is constructed, a series of nano antibody molecules specifically targeting claudin 18.2 are screened from the alpaca immune bacteriophage display library, and functions and applications of the nano antibody are verified at CLDN18.2 antigen protein and CLDN18.2 target cell levels.

The present invention relates to the combined use of Fc [gamma] RIIb (CD32B) and CD20 specific antibodies, and specifically provides a method of treating a patient having a target cell expressing Fc [gamma] RIIb, the method comprising administering in combination (i) an antibody molecule that specifically binds to a surface antigen of the target cell, the antibody molecule having an Fc domain capable of binding Fc [gamma] RIIb; and (ii) an agent that inhibits or reduces binding between the Fc domain of the antibody molecule and Fc [gamma] RIIb, characterized in that the patient is selected on the basis of an increase in Fc [gamma] RIIb expression level of its target cell.

The present application relates to antibody molecules that bind both PD-L1 and CD137 and are able to induce agonism of CD137. The antibody molecules comprise a CDR-based binding site for PD-L1, and a CD137 antigen-binding site that is located in a constant domain of the antibody molecule. The antibody molecules of the invention find application, for example, in the treatment of diseases, such as cancer.

The application relates to the diagnosis and treatment of diseases, including cancer, chronic infectious diseases, autoimmune diseases, inflammatory disorders, as well as the prevention of transplant rejection. The invention provides, and involves the use of, antibody molecules that bind CD28 in a non super-agonistic manner and which also bind to CTLA-4. The antibody molecules may form part of a bispecific molecule which binds e.g. a tumor associated antigen or a further T cell antigen, such as CD3.

The present application provides chimeric anti-CD27 antibody molecules and encoding nucleic acids and expression vectors thereof. The anti-CD27 antibody molecules of the present application can specifically bind to CD27 and have effects of stimulating lymphocyte proliferation, activating lymphocytes, etc.

Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and / or diagnose cancerous or infectious disorders.

The invention belongs to the technical field of biological medicine, and particularly relates to a DLL3 targeted binding protein and application. The DLL3 targeted binding protein has an amino acid sequence as shown in SEQ ID NO. 1, SEQ ID NO. 2 or SEQ ID NO. 3. The DLL3 targeted binding protein disclosed by the invention can be specifically bound with DLL3, the binding affinity reaches nM level, the molecular weight is about 18kDa which is far less than that of a traditional antibody molecule, and the DLL3 targeted binding protein has stronger tissue penetrability and lower immunogenicity. Related tests show that the DLL3 targeted binding protein disclosed by the invention can be used for diagnosis, treatment and drug delivery of DLL3 positive tumors, and has a wide clinical application prospect.

The invention provides a method of treating a patient having target cells that express FcγRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcγRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcγRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcγRIIb.

Humanized antibody molecules that specifically bind to CD138 are disclosed. The humanized antibody molecules can be used to treat, prevent, and / or diagnose disorders, such as multiple myeloma.

The present invention relates to a test kit for performing an assay to detect and measure at least one autoantibody molecule in a subject developing type 1 diabetes (T1D). The invention more specifically relates to a recombinant antigen molecule fused to a bioluminescent reporter protein to detect an autoantibody molecule against a self-antigen. Said self-antigen is preferably expressed by pancreatic islet beta cells and include insulin, proinsulin, Glutamate decarboxylase 65, islet antigen 2, and Zinc transporter 8. More specifically, the present invention relates to an assay comprising a set of at least three recombinant antigen molecules in a single composition, the antigen molecules being selected from the list comprising recombinant human Glutamate decarboxylase 65, recombinant human islet antigen 2, recombinant human Zinc transporter 8, recombinant human insulin, and recombinant human proinsulin. The invention further relates to methods for determining the presence and / or level of at least one autoantibody molecule in a sample from a human subject developing T1D using said recombinant antigen molecules. According to the invention, the presence, absence, or amount of one or more autoantibody molecules against said self-antigens is determined with a luciferase immune precipitation system (LIPS) assay or a modified version of a LIPS assay, i.e., a solid phase capture LIPS (scLIPS) assay.

The present invention relates to a linker unit-cytotoxic small molecule drug, an antibody specifically binding to target mucoprotein 17 (MUC17), an antibody drug conjugate and uses thereof, and a composition and a detection system containing the antibody molecule, the linker unit-cytotoxic small molecule drug and the antibody drug conjugate.

The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an antigen selected from the group consisting of Prostate Stem Cell Antigen (PSCA), B-Lymphocyte antigen CD19 (CD19), hepatocyte growth factor receptor (C-MET), Endosialin, the EGF-like domain 1 of EpCAM, encoded by exon 2, Fibroblast activation protein alpha (FAP alpha) and Insulin-like growth factor I receptor (IGF-IR or IGF-1R). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.